SARATOGA, CA & CHARLOTTESVILLE, VA, USA I August 13, 2013 I TheMyelin Repair Foundation (MRF) and Gencia Corporation today announced a collaboration to advance myelin repair therapeutic development for Multiple Sclerosis (MS). Through its unique Accelerated Research Collaboration™ (ARC™) model, the Myelin Repair Foundation will partner with Gencia Corporation to assess the myelin regenerating capabilities of the company’s proprietary therapeutic compounds for MS.
Through this unique partnership, Gencia Corporation will work closely with researchers at the Myelin Repair Foundation’s Translational Medicine Center, a laboratory facility dedicated to the evaluation of promising multiple sclerosis candidates for myelin repair. Led by MRF personnel with extensive biopharma experience moving therapeutic compounds into the clinic, the MRF Translational Medicine Center investigates and advances promising myelin repair drug targets toward commercialization.
“The Myelin Repair Foundation’s patient-centric, collaborative approach to develop the next generation of MS therapeutics makes them an ideal partner for us to bring new treatments to the clinic,” said President and CEO Allen Cunningham from Gencia Corporation. “We are excited to work side by side with MRF, utilizing their novel myelin repair research tools and assays at the MRF Translational Medicine Center. With this partnership, we are well positioned to expedite myelin repair therapeutics development forward, meeting the needs of MS patients.”
“Gencia’s forward-thinking approach to remyelination aligns nicely with our goal to bring the next generation of MS treatments to patients,” said Chief Research Officer Dr. Jay Tung, Ph.D, from the Myelin Repair Foundation. “We are thrilled to be working with Gencia to examine new ways to treat MS. As a non-profit organization, we seek to partner with innovative companies doing exciting MS research in myelin repair.”
The Myelin Repair Foundation’s rigorous, industry-leading Translational Medicine Platform consists of its Translational Medicine Center, contract research organizations and the MRF’s research consortium. The goal of the MRF Translational Medicine Platform is to ensure comprehensive validation of potential therapeutics into clinical development.
About the Myelin Repair Foundation
The Myelin Repair Foundation (MRF) (www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for Multiple Sclerosis. Its Accelerated Research Collaboration™ (ARC™) model is designed to optimize the process of medical research, drug development and the delivery of new patient treatments.
About Gencia Corporation
Gencia Corporation is a privately held biopharmaceutical company focused on discovering and developing novel therapeutics to treat disease. The company’s programs leverage the fundamental role that mitochondria play in health, aging and disease. Gencia’s pipeline contains biologics and small molecules for the treatment of central nervous system (CNS) disease, inflammation and rare genetic disorders.
SOURCE: The Myeline Repair Foundation
Post Views: 155
SARATOGA, CA & CHARLOTTESVILLE, VA, USA I August 13, 2013 I TheMyelin Repair Foundation (MRF) and Gencia Corporation today announced a collaboration to advance myelin repair therapeutic development for Multiple Sclerosis (MS). Through its unique Accelerated Research Collaboration™ (ARC™) model, the Myelin Repair Foundation will partner with Gencia Corporation to assess the myelin regenerating capabilities of the company’s proprietary therapeutic compounds for MS.
Through this unique partnership, Gencia Corporation will work closely with researchers at the Myelin Repair Foundation’s Translational Medicine Center, a laboratory facility dedicated to the evaluation of promising multiple sclerosis candidates for myelin repair. Led by MRF personnel with extensive biopharma experience moving therapeutic compounds into the clinic, the MRF Translational Medicine Center investigates and advances promising myelin repair drug targets toward commercialization.
“The Myelin Repair Foundation’s patient-centric, collaborative approach to develop the next generation of MS therapeutics makes them an ideal partner for us to bring new treatments to the clinic,” said President and CEO Allen Cunningham from Gencia Corporation. “We are excited to work side by side with MRF, utilizing their novel myelin repair research tools and assays at the MRF Translational Medicine Center. With this partnership, we are well positioned to expedite myelin repair therapeutics development forward, meeting the needs of MS patients.”
“Gencia’s forward-thinking approach to remyelination aligns nicely with our goal to bring the next generation of MS treatments to patients,” said Chief Research Officer Dr. Jay Tung, Ph.D, from the Myelin Repair Foundation. “We are thrilled to be working with Gencia to examine new ways to treat MS. As a non-profit organization, we seek to partner with innovative companies doing exciting MS research in myelin repair.”
The Myelin Repair Foundation’s rigorous, industry-leading Translational Medicine Platform consists of its Translational Medicine Center, contract research organizations and the MRF’s research consortium. The goal of the MRF Translational Medicine Platform is to ensure comprehensive validation of potential therapeutics into clinical development.
About the Myelin Repair Foundation
The Myelin Repair Foundation (MRF) (www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for Multiple Sclerosis. Its Accelerated Research Collaboration™ (ARC™) model is designed to optimize the process of medical research, drug development and the delivery of new patient treatments.
About Gencia Corporation
Gencia Corporation is a privately held biopharmaceutical company focused on discovering and developing novel therapeutics to treat disease. The company’s programs leverage the fundamental role that mitochondria play in health, aging and disease. Gencia’s pipeline contains biologics and small molecules for the treatment of central nervous system (CNS) disease, inflammation and rare genetic disorders.
SOURCE: The Myeline Repair Foundation
Post Views: 155
